Skip to main content

RYTHM, Inc. Announces Amendments to License Agreements with Green Thumb Industries

ROLLING MEADOWS, Ill., April 01, 2026 (GLOBE NEWSWIRE) — RYTHM, Inc. (Nasdaq: RYM) (“RYTHM” or the “Company”), America’s THC Company, today announced amendments to its existing trademark and recipe license agreements with an indirect wholly-owned subsidiary of Green Thumb Industries Inc. (“Green Thumb”). RYTHM and Green Thumb have amended their existing trademark and recipe license agreements for the use of brand intellectual property which includes RYTHM, incredibles, Beboe, Dogwalkers, Doctor Solomon’s, &Shine, and Good Green. Effective April 1, 2026, Green Thumb will pay RYTHM an aggregate fixed annual cash fee of $70 million, subject to an annual increase equal to two times a Consumer Price Index-based escalator. “These amendments create a framework that strengthens our licensing arrangement with Green Thumb over the long...

Continue reading

 Green Thumb Industries Announces Amendment to Brand Transactions with RYTHM, Inc.

CHICAGO and VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced amendments to its brand licensing agreements with wholly-owned subsidiaries of RYTHM, Inc. (“RYTHM” or “RYM”) (Nasdaq: RYM). Effective April 1, 2026, GTI Core, LLC (“GTI Core”), an indirect wholly-owned subsidiary of the Company, has amended its existing Trademark and Recipe License Agreements with VCP IP Holdings, LLC and MC Brands LLC, both wholly-owned subsidiaries of RYTHM. Under the amended agreements, licensing fees transition from revenue-based fees to recurring fixed fees of $70 million cash per year collectively for the license rights to RYTHM...

Continue reading

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) — NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the Company’s common shares on March 31, 2026. Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series of warrants to purchase an aggregate of 687,270 common shares at an exercise price of $3.025 per share. The offering includes participation from...

Continue reading

MiniLuxe Announces Follow-On Investment of up to US$1.75M from Flow Capital

Company expands on its relationship with Flow Capital. Boston, MA, April 01, 2026 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX)(“MiniLuxe” or the “Company”), the pioneer in clean nail care and ethical nail services, is pleased to announce that Flow Capital Corporation (TSXV:FW) (“Flow Capital”), a leading provider of flexible growth capital and alternative debt solutions, has completed a follow-on investment of up to US$1.75M pursuant to its existing term loan with the Company, bringing the total amount available to the Company under the facility to up to US$7.925 million. Under the new tranche of the loan, an initial advance of US$1.35 million was funded to the Company on closing, and the Company is also eligible to receive an additional advance of up to US$400,000, subject to the satisfaction of certain financing milestones,...

Continue reading

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4-associated retinopathiesMALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies). “This enrollment milestone for a pivotal trial underscores the tremendous progress our team is making toward bringing a transformative...

Continue reading

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment of a serious or life-threatening condition MIAMI, April 01, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. “We appreciate the FDA’s decision that PAS-004 meets the criteria for Fast Track designation for this indication,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “The ability...

Continue reading

Whitestone REIT Adds Premier Tenant at BLVD Place, Signs Agreement for Parkhill’s Houston Headquarters

Multidisciplinary architecture and engineering firm to occupy approximately 5,800 square feet at the mixed-use center HOUSTON, April 01, 2026 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR), a neighborhood-focused owner and operator of open-air shopping centers in Texas and Arizona, today announced it has signed an approximately 5,800-square-foot lease with Parkhill, a multidisciplinary architecture and engineering firm, to open a new office presence in Houston at BLVD Place located in the prestigious Uptown District. The agreement highlights the type of high-credit-quality tenants that are being drawn to the mixed-use center because of its prime location and amenities. Parkhill’s second-floor workspace at BLVD Place epitomizes the type of dynamic setting that is critical for employee retention and attracting the next generation...

Continue reading

Cespira’s Hydrogen HPDI™ Fuel System Now in On-Road Testing

Advancing HPDI Technology for Hydrogen Fuel VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport” or the “Company”) (TSX:WPRT / Nasdaq:WPRT), a leading supplier of advanced alternative fuel systems and components for the global transportation industry, is pleased to announce that its joint venture, Cespira and their HPDI™ fuel system technology will be utilized by Volvo in on-road testing of heavy-duty trucks powered by hydrogen. Volvo has indicated that a commercial launch is planned to take place prior to 2030. “On-road testing is a key milestone in demonstrating that Cespira’s hydrogen HPDI fuel system is a cost-effective solution that operates on a zero-carbon fuel while delivering best-in-class power, torque, and efficiency,” said Dan Sceli, Chief Executive Officer...

Continue reading

LVMH: AVAILABILITY OF THE 2025 UNIVERSAL REGISTRATION DOCUMENT

Paris, April 1st, 2026 LVMH Moët Hennessy Louis Vuitton announces the availability of its 2025 Universal Registration Document (URD), in accordance with applicable regulations. The French version of this document was filed with the “Autorité des marchés financiers” (AMF) on March 31st, 2026 in ESEF format (European Single Electronic Format) under the reference D.26-0195. The English translation of this document may be consulted on the Company’s website www.lvmh.com (under Investors / Investors and Analysts / Publications). It is equally available on the AMF website: www.amf-france.org. This document includes in particular: – the 2025 annual financial report;– the Board of Directors’ management report, to which are attached the Board of Directors’ report on corporate governance and the sustainability report;– the Statutory...

Continue reading

Aura Reports Updated Mineral Reserves and Mineral Resources For The Year-Ended 2025, Highlighting year of Significant Growth in Mineral Reserve and Resource Portfolio

ROAD TOWN, British Virgin Islands, April 01, 2026 (GLOBE NEWSWIRE) — Aura Minerals Inc. (NASDAQ: AUGO) (B3: AURA33) (“Aura” or the “Company”) is pleased to report updated Mineral Reserves and Mineral Resources (“MRMR”) for its six operating mines: Aranzazu Mine, Apoena Mines, Minosa Mine, Almas Mine, Borborema Mine and MSG Mine, as well as its development projects including Era Dorada and Matupá. Between 2024 and 2025, Aura updated its MRMR models to reflect new data. Updates were driven by exploration drilling, revised geological interpretations, changes in mining methods, extraction plans, and economic parameters, including commodity prices that impacted cut-off grades and reserve classification, as well as M&A activities. The Company is also pleased to report that it has filed its annual report on Form 20-F for the fiscal...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.